SCHEMBL7854681

SCHEMBL7854681

C=CC(/C=C\c1ccc(OC)cc1)c1ccc(OC)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.53
ALDH1A1 P00352 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
MAPT P10636 1/20 0.53
ALOX15 P16050 1/20 0.53
KDM4E B2RXH2 3/20 0.48
LMNA P02545 2/20 0.48
TP53 P04637 1/20 0.48
TSHR P16473 1/20 0.48
CYP1A2 P05177 3/20 0.47
CYP1A1 P04798 3/20 0.47
CYP1B1 Q16678 3/20 0.47
TRPA1 O75762 1/20 0.47
RELA Q04206 1/20 0.47
ESR1 P03372 2/20 0.46
PTGS2 P35354 2/20 0.46
AHR P35869 2/20 0.46
ABL1 P00519 1/20 0.46
TTR P02766 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL805124 0.92 MAPT (0.50) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
SCHEMBL7861615 0.92 MAPT (0.50) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
SCHEMBL7864584 0.92 MAPT (0.50) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
SCHEMBL7861301 0.83 CYP3A4 (0.37) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
SCHEMBL13558429 0.78 RELA (0.41) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
SCHEMBL7854650 0.78 RELA (0.41) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
Nyasol SCHEMBL776219 0.77 APP (0.43) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
Nyasol SCHEMBL776218 0.77 APP (0.43) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
Nyasol SCHEMBL799383 0.77 APP (0.43) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT
Nyasol SCHEMBL8416158 0.77 APP (0.43) CYP3A4ALDH1A1CYP2C9CYP2C19MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120277169-A1 NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES BIONOVO, INC. (US) 2012-11-01 US disclosed
US-20090312274-A1 Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases BIONOVO, INC. (US) 2009-12-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312274-A1 Nyasol and Analogs Thereof for the Treatment of Estrogen Receptor Beta-Mediated Diseases ESR2, ESR1, ESRRA CYP3A4 3838/4885ALDH1A1 3223/4885CYP2C9 4584/4885
US-20120277169-A1 NYASOL AND ANALOGS THEREOF FOR THE TREATMENT OF ESTROGEN RECEPTOR BETA-MEDIATED DISEASES ESR2, ESR1, ESRRA CYP3A4 3838/4885ALDH1A1 3223/4885CYP2C9 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.